Many biomarkers directly reflect AD pathology (e.g. phosphorylated tau or Aβ1-42 in CSF or amyloid PET), whilst others provide evidence of neuronal injury which may be indirect evidence of AD or other neurodegenerative conditions. The gene discussed is MAPT; the disease is Alzheimer disease.